Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management?

References

• Mushlin AI, Ghomrawi H. Health care reform and the need for comparative-effectiveness research. N. Engl. J. Med.362(3), e6 (2010).
   PubMed Web of Science ®Google Scholar
• Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine? N. Engl. J. Med.360(19), 1925–1927 (2009).
   PubMed Web of Science ®Google Scholar
• Valid concerns. Nature463(7280), 401–402 (2010).
   Google Scholar
• Lin K, Lipsitz R, Miller T, Janakiraman S; US Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med.149(3), 192–199 (2008).
   PubMed Web of Science ®Google Scholar
• AJCC Cancer Staging Manual (7th Edition). Edge SE, Byrd DR, Carducci MA, Compton CA (Eds). Springer, NY, USA (2009).
   Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science266, 66–71 (1994).
   PubMed Web of Science ®Google Scholar
• Wooster R Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature378, 789–792 (1995).
   PubMed Web of Science ®Google Scholar
• Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin. Genet.76(1), 1–18 (2009).
   PubMed Web of Science ®Google Scholar
• Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature392(6674), 402–405 (1998).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol.17, 14–17 (2010).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360(14), 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature458(7236), 290–292 (2009).
   PubMedGoogle Scholar
• Roukos DH. Tzakos A, Zografos G. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev. Anticancer Ther.9(10), 1413–1416 (2009).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med.353(16), 1734–1736 (2005).
   PubMed Web of Science ®Google Scholar
• Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev. Anticancer Ther.10(2), 123–128 (2010).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Mea kulpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn.9(3), 217–221 (2009).
   PubMed Web of Science ®Google Scholar
• de Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med.361(7), 653–63 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Isolated tumor cells in breast cancer. N. Engl. J. Med.361, 1994–1995 (2009).
   PubMedGoogle Scholar
• Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science321(5897), 1801–1806 (2006).
   Google Scholar
• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239), 719–724 (2009).
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Stephens PJ, O’Meara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature463, 184–190 (2010).
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature463, 191–196 (2010).
   PubMed Web of Science ®Google Scholar
• Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature461(7265), 809–813 (2009).
   PubMed Web of Science ®Google Scholar
• Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature462(7276), 1005–1010 (2009).
   PubMed Web of Science ®Google Scholar
• Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol.26, 1135–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med.360(8), 790–800 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J. Clin. Oncol.27(8), 1337–1338 (2009).
   PubMedGoogle Scholar
• Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer2(5), 331–341 (2002).
   PubMed Web of Science ®Google Scholar
• Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature461(7261), 218–223 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev. Mol. Diagn.10(1), 33–48 (2010).
   PubMed Web of Science ®Google Scholar
• Deisboeck TS. Personalizing medicine: a systems biology perspective. Mol. Syst. Biol.5, 249 (2009).
   PubMedGoogle Scholar
• Goldstein DB. 2020 visions. Personalized medicine. Nature463, 27 (2010).
   Google Scholar
• Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics11(3), 283–287 (2010).
   PubMed Web of Science ®Google Scholar